The observation of GLP-1 agonist’s impact on cardiovascular outcomes is particularly significant given the diverse galaxy of existing anti-diabetic medications and the need to identify therapies that not only manage glycemic control but also manage the increased T2DM-associated cardiovascular risks. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.